Borrelia afzelii Pko DbpA Antigen BA121R01

$1,054.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Borrelia afzelii Pko DbpA Antigen, recombinant
Suitable for detection of IgA, IgG & IgM antibodies in ELISA
Lot specific concentration, specified in mg/mL
1 mg

SKU: BA121R01 Category: Infectious disease proteins Tags: antigen, Borrelia

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Borrelia afzelii Pko DbpA
species reactivity	Borrelia afzelii (lyme disease)
applications	ELISA
assay type	Indirect & quantitative
available size	1 mg

Borrelia afzelii Pko DbpA Antigen BA121R01

kit
Research area Infectious Disease
Storage Store -65°C or below. Avoid repeated freeze-thaw cycles.
Form liquid
Associated products Borrelia garninii Antigen (BA121GVS) Borrelia afzelii Pko DbpA Antigen (BA121R01) Borrelia afzelii Pko OspC Antigen (BA121R02) Borrelia afzelii Antigen (BA121VS) Borrelia burgdorferi IgG Control Serum (BC121G) Borrelia burgdorferi IgG Control Serum (BC121G) Borrelia burgdorferi IgM Control Serum (BC121M) Borrelia burgdorferi IgG ELISA Kit (ESR121G) Borrelia burgdorferi IgM ELISA Kit (ESR121M)

target relevance
Borrelia afzelii
Description Spirochete bacterium that causes Lyme borreliosis, particularly cutaneous manifestations
Structure Borrelia afzelii is a Gram-negative, highly motile spirochete belonging to the Borrelia burgdorferi sensu lato complex and the family Spirochaetaceae. The bacterium possesses a characteristic helical morphology and periplasmic flagella that facilitate corkscrew-like movement through host tissues. Borrelia afzelii is transmitted primarily through the bite of infected Ixodes ticks and is maintained in natural transmission cycles involving ticks and small mammalian reservoir hosts, particularly rodents. The species is widely distributed throughout Europe and Asia and is one of the most common causes of Lyme borreliosis in these regions. Compared with other Lyme disease-associated Borrelia species, B. afzelii demonstrates a strong affinity for skin tissues and is frequently associated with chronic dermatological manifestations of infection. Following inoculation by an infected tick, the organism can disseminate from the skin to other tissues and persist for extended periods if untreated.
Diagnosis The diagnosis of Borrelia afzelii infection is performed through a combination of clinical evaluation, serological testing, and molecular methods. Laboratory diagnosis typically follows a two-tier testing strategy consisting of an initial ELISA or immunoassay followed by confirmatory immunoblot analysis when appropriate. Detection of Borrelia-specific IgM and IgG antibodies provides evidence of infection, although antibodies may not be detectable during the earliest stages of disease. Polymerase chain reaction (PCR) assays may be used to detect Borrelia DNA in skin biopsies, synovial fluid, cerebrospinal fluid, or other clinical specimens. Histopathological examination of affected skin tissue may support the diagnosis in patients with chronic cutaneous manifestations. Clinical findings, laboratory results, and a history of tick exposure are all important components of diagnosis.
Symptoms Borrelia afzelii infection commonly presents with manifestations of Lyme borreliosis following the bite of an infected tick. Early symptoms may include erythema migrans, an expanding skin lesion that develops at the site of inoculation and is often accompanied by fatigue, fever, headache, muscle aches, and joint pain. Compared with other Borrelia species, B. afzelii is particularly associated with chronic skin involvement, including acrodermatitis chronica atrophicans (ACA), a progressive skin disorder characterized by discoloration, thinning, and atrophy of the skin, typically affecting the extremities. Additional manifestations may include intermittent arthritis, neuropathic symptoms, and generalized malaise. Although neurological and articular complications can occur, cutaneous disease is a hallmark feature of B. afzelii infection. Early diagnosis and treatment are important to prevent chronic manifestations and long-term complications.

Data

FAQ & Publications

Frequently Asked Questions

What is the primary application of the Borrelia afzelii Pko DbpA Antigen BA121R01?

The Borrelia afzelii Pko DbpA Antigen BA121R01 is primarily used for the detection of IgA, IgG, and IgM antibodies in ELISA assays.

Which species does the Borrelia afzelii Pko DbpA antigen specifically target?

This antigen is reactive to Borrelia afzelii, a species of Borrelia that can cause a variant of Lyme disease in humans.

How should the Borrelia afzelii Pko DbpA Antigen be stored to maintain stability?

The antigen should be stored at -65°C or below, and repeated freeze-thaw cycles should be avoided to preserve its activity.

What is the form and available quantity of the Borrelia afzelii Pko DbpA Antigen BA121R01?

The product is supplied in liquid form with an available size of 1 mg per vial.

Is there specific information on the concentration of the Borrelia afzelii Pko DbpA Antigen provided with the product?

Yes, the lot-specific concentration is provided and specified in mg/mL with each product batch.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.